Companies › AVTX

AVALO THERAPEUTICS INC (AVTX)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001534120 · EDGAR filings · Updated 2026-07-28

AVALO THERAPEUTICS INC (AVTX) has reported institutional ownership of 136.5%, with 97 institutional managers holding positions valued at $464.2M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings, triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04).

Filings this week (2)

• 2026-07-28 — Prospectus supplement (424B3) filed
• 2026-07-27 — SCHEDULE 13G filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-17 — Shelf registration (S-3) filed
• 2026-07-06 — SCHEDULE 13G/A filed
• 2026-07-02 — Insider transaction reported (Form 4)
• 2026-07-02 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, AVALO THERAPEUTICS INC has 97 institutional holders and institutional ownership of 136.5%.

Insider activity

Insiders reported 29 transactions (0 buys, 3 sells) across 11 reporting insiders, with a net reported value of −$574.7K.

Data flags from SEC filings

Related companies

SANA BIOTECHNOLOGY INC (SANA) · 4D MOLECULAR THERAPEUTICS IN (FDMT) · BIOVENTUS (BVS) · CRESCENT BIOPHARMA INC. (CBIO) · LEXEO THERAPEUTICS INC (LXEO) · INMODE LTD (INMD)